360Biolabs, a Bioagilytix company

Enabling Future Medicines

Australia's most comprehensive bioanalytical laboratory offers a full suite of pharmacokinetic and pharmacodynamic assays for your early-phase clinical studies.

Team of high performing scientists working together in state-of-the-art laboratory conducting bioanalytical testing

Our global footprint allows you to use the Australian advantage to expedite your Phase 1 study & expand into Phase 2 with our global BioAgilytix laboratories.

Explore BioAgilytix Global Team
6
Global Locations
50
PhD Scientists
140
Local Team
1000
Global Team

360biolabs Comprehensive Services

At 360biolabs, we value science-driven excellence, innovation, quality, and reliable bioanalytical testing. Our passion for the science of assay development, biomarker analysis, and pharmacokinetic assessments drives our delivery of our wide range of comprehensive services.

Advancing
Health Globally

BioAgilytix's state-of-the-art laboratories extend to 3 countries and 6 facilities. We support all phases of drug development with local expertise and global resources. Experience world-class bioanalytical excellence that accelerates your breakthroughs.

Map of the world

Australian Advantage
Accelerating Your Global Clinical Research

Speed

Australia offers a fast and pragmatic regulatory environment for early-phase clinical (no IND required).

Cost

The Australian government offers an attractive R&D tax incentive of 43.5% to eligible companies.

Quality

Australia is an OECD country and a member of the OECD Mutual Acceptance of Data (MAD) system. Data from studies conducted in Australia can be used to support international regulatory applications.

Stay Connected

Stay connected with us on LinkedIn and see service updates, events, seminars, and company updates.

Explore 360biolabs: Services, Insights & Innovation

Pipetting for accurate, precise and robust sample analysis
Scientists working in biosafety cabinet preparing PBMC isolation for ELISpot